Benzinga | Jan 14, 2021 07:35AM EST

Invitae Announces Launch Of New Project With Multiple Pharmaceutical Companies To 'develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs'

SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ -- Invitae Corporation (NYSE:NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis and Genentech, a member of the Roche Group, to develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs. The companies are working together to standardize how MRD data is generated and assessed in clinical trials helping to better establish the clinical utility of MRD as a biomarker in AML.